CLGN (CLGN) Stock Price & Analysis
CLGN (CLGN) rose 0.27% to USD 0.37 as of June 10, 2026 at 09:32 UTC, according to Nexqual real-time market data.
CLGN last closed at USD 0.37; the session ranged USD 0.35–0.37 on volume of 44,448 shares. Market capitalization is $5.35M, with a 52-week range of USD 0.27–3.23 (NCM). Source: Nexqual, June 10, 2026 at 09:32 UTC.
Key Statistics (as of June 10, 2026 at 09:32 UTC)
| Price | USD 0.37 |
|---|---|
| Change | ▲ 0.27% (up) |
| Previous Close | USD 0.37 |
| Open | USD 0.37 |
| Day Range | USD 0.35 – 0.37 |
| 52-Week Range | USD 0.27 – 3.23 |
| Volume | 44,448 shares |
| Market Cap | $5.35M |
| Exchange | NCM |
Technical Analysis (CLGN)
Nexqual's technical model rates CLGN "STRONG SELL" based on 0 bullish and 5 bearish signals across 123 daily candles, as of June 10, 2026 at 09:32 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 39.82 (neutral) |
| vs SMA50 | Below (USD 0.41) |
| MACD | -0.01 (negative) |
Analyst Ratings (CLGN)
Wall Street analysts rate CLGN "None", per Nexqual as of June 10, 2026 at 09:32 UTC.
| Consensus Rating | None |
|---|---|
| Buy / Hold / Sell | 0 / 1 / 0 |
Earnings (CLGN)
| Next Earnings Date | 2026-08-19 |
|---|
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.25 vs est -0.19 ▼ miss |
| 2025-09-30 | USD -0.27 vs est 0.16 ▼ miss |
| 2025-06-30 | USD -0.28 vs est -0.1 ▼ miss |
| 2025-03-31 | USD -0.13 vs est -0.04 ▼ miss |
Source: Nexqual, June 10, 2026 at 09:32 UTC.
Financials & Fundamentals (CLGN)
| Total Revenue | $389,000 |
|---|---|
| Revenue Growth (YoY) | -96.40% |
| Gross Margin | -147.56% |
| Operating Margin | -4267.12% |
| Profit Margin | +0.00% |
| ROE | -151.99% |
| Debt / Equity | 54.22 |
| Current Ratio | 2.27 |
| Total Cash | $4.26M |
| Total Debt | $2.65M |
| Free Cash Flow | $-6.68M |
Source: Nexqual, June 10, 2026 at 09:32 UTC.
Financial Health Score (CLGN)
Nexqual rates CLGN's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 09:32 UTC.
| Growth | Strong — Revenue +291% YoY (annual) |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Strong — $4M cash vs $3M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$7M, burning cash |
| Efficiency | Critical — ROE -152%, ROA -61.3% |
Ownership (CLGN)
| Insider Ownership | +26.87% |
|---|---|
| Institutional Ownership | +12.03% |
| Shares Outstanding | 14.42M |
| Float | 10.15M |
| Short % of Float | +0.40% |
Source: Nexqual, June 10, 2026 at 09:32 UTC.
Leadership (CLGN)
CLGN is led by Yehiel Tal (age 73), CEO & Chairman, per Nexqual as of June 10, 2026 at 09:32 UTC.
| CEO & Chairman | Yehiel Tal (age 73) |
|---|---|
| Deputy CEO & CFO | Eran Rotem (age 57) |
| Vice President of Operations | Oren Fahimipoor (age 43) |
| Vice President of Legal | Bar Abelis |
| Vice President of Human Resources | Hadas Dreiher Horowitz (age 48) |
Major Backers & Investors (CLGN)
Notable institutional backers of CLGN include Villere St. Denis J. & Co. LLC, Pinnacle Associates, Ltd., Brown Advisory Inc., according to Nexqual as of June 10, 2026 at 09:32 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Villere St. Denis J. & Co. LLC | 5.43% |
| Pinnacle Associates, Ltd. | 4.92% |
| Brown Advisory Inc. | 1.06% |
| Armistice Capital, LLC | 0.57% |
| Pathstone Holdings, LLC | 0.51% |
| Citadel | 0.29% |
| Legacy Wealth Managment, LLC/ID | 0.21% |
| Renaissance Technologies | 0.15% |
Source: Nexqual, June 10, 2026 at 09:32 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| VMD | Viemed Healthcare, Inc. | USD 9.92 | ▼ 0.5% |
| MDWD | MediWound Ltd. | USD 14.3 | ▲ 0.85% |
| SLGL | Sol-Gel Technologies Ltd. | USD 76.22 | ▼ 2.26% |
| FKWL | Franklin Wireless Corp. | USD 2.78 | ▼ 2.8% |
| CSBR | Champions Oncology, Inc. | USD 5.79 | ▲ 2.48% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 09:32 UTC. This page is informational and not investment advice.